Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Selective Serotonin Reuptake Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Selective Serotonin Reuptake Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Selective Serotonin Reuptake Inhibitors, commonly known as SSRIs, are a class of widely prescribed antidepressant medications. They play a vital role in the management of various mental health conditions, particularly depression and anxiety disorders. SSRIs work by targeting serotonin, a neurotransmitter that regulates mood, emotions, and several physiological functions, making them essential tools in the field of psychopharmacology.
SSRIs act on the serotonin transporter (SERT) molecules, which are responsible for reabsorbing serotonin into nerve cells after its release. The primary mechanism of SSRIs involves blocking the reuptake of serotonin by inhibiting SERT. By doing so, SSRIs increase the concentration of serotonin in the synaptic cleft, leading to enhanced neurotransmission and improved mood regulation. SSRIs primarily treat depression and various anxiety disorders, including generalized anxiety disorder, social anxiety disorder, and panic disorder. Additionally, they are prescribed for obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and certain eating disorders. According to the World Health Organization (WHO), depression is a major global health concern, affecting more than 264 million people worldwide, making SSRIs a crucial intervention in addressing this prevalent mental health condition. Extensive research is being conducted globally to discover new and novel molecules to be used, like vilazodone, that is used for the treatment of many indications like Major Depressive Disorder (MDD). The development and launch of new products will thus increase the market's revenue in the forecasted years.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. 7 companies have various products in their pipelines, with 17 products in different stages of clinical trials – 1 in Phase 4, 1 in Phase 3, and 4 in Phase 2 of the clinical trials.
Approved Serotonin Uptake Inhibitor molecules
Drugs in the Pipeline of Selective Serotonin Reuptake Inhibitors
Clinical Activity and Developments of Selective Serotonin Reuptake Inhibitors
As of July 2023, 7 companies have approximately 17 products for 240 diseases. For these diseases, 219 trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Viibryd (vilazodone) |
29 |
|
ammoxetine hydrochloride |
4 |
|
mitizodone phosphate (HEC113995 PA) |
4 |
|
aripiprazole/sertraline (ASC-01) |
3 |
|
hypidone hydrochloride (HHT101)
|
3 |
Selective Serotonin Reuptake Inhibitors (SSRIs) have a diverse range of indications in the field of psychiatry and mental health. Among the various applications, SSRIs find the most significant use in treating major depressive disorder (MDD), where they serve as a first-line therapy due to their effectiveness in alleviating depressive symptoms and improving overall mood. Additionally, SSRIs are widely prescribed for generalized anxiety disorder (GAD) and social anxiety disorder (SAD), relieving excessive worry and anxiety in these conditions. They also play a crucial role in managing panic disorder, effectively reducing the frequency and intensity of panic attacks. Furthermore, SSRIs are used in treating obsessive-compulsive disorder (OCD), helping to alleviate distressing and intrusive thoughts, and post-traumatic stress disorder (PTSD), assisting in managing traumatic stress-related symptoms. Their versatility extends to conditions like bulimia nervosa and premenstrual dysphoric disorder (PMDD), further showcasing their importance as essential tools in modern psychiatric care.
Depressive disorder or Depression is the most common mental disorder globally, with an estimated 5% of adults suffering from it, according to the WHO report. Depression affects women more than men. An estimated 8% global population, near to 280 million people, experiences depression, including 5% of adults and 5.7% of adults older than 60 years of age. According to a research study of 2020 in the USA, around 21 million (8.5%) adults had at least 1 major depressive episode, with the prevalence highest amongst the age group of 18-25 years (17%). According to the Anxiety and Depression Association of America, in 2022, 3.1% or 6.8 million people in the USA will be affected by Generalized Anxiety Disorder (GAD), yet only 43.2% receive treatment. Thus, there is an opportunity for the market players globally to launch their products and expand their market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Viibryd (vilazodone) has been approved by the FDA as a Serotonin Uptake Inhibitor.
These are used for the treatment of various disorders like Major Depressive Disorders (MDD), Generalized Anxiety Disorder (GAD), obsessive-compulsive disorder (OCD), and others.
AbbVie, CSPC Pharma, HEC Pharma Co., Ltd, and Otsuka Pharmaceutical are some major market players for Selective Serotonin Reuptake Inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and rising incidence of various types of disorders like MDD, OCD, GAD, and others are the key opportunities for Selective Serotonin Reuptake Inhibitors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.